Meet The Team

A diverse and dedicated team with a wealth of experience across a broad range of industries and technologies.

Our Scientific Team

Mazin
Nicola

CTO and Co-Founder
A chartered chemist with 40 years pharmaceutical experience. 26 years of medicinal product design and development. Over 20 years as a Senior Scientist at GSK.

Read more

Mazin Nicola
Chief Technical Officer

Maz is a medicinal biotechnology research and development scientist, a Chartered Chemist and a member of the Royal Society of Chemistry with over 40 years experience in the pharmaceutical industry.

26 years experience in downstream process design and development within the pharmaceutical and medical cannabis industry followed by 7 years as Technical Director/consultant involved in supercritical fluids and liquefied gas processes.

Specialities include medicinal biotech process design and implementation including anti-infectives, anti-depressants, cognitive enhancers and enzyme inhibitors.

Additionally, Mazin has the title of Visiting Research Scientist at the University of Sussex.

Dr Daniel
Guest

Principal Scientist
A research and development chemist specialising in chemical process engineering and organic...

Read more
Dr Daniel Guest
Principal Scientist
Received his M.S in chemical engineering in 2011 from Nottingham Trent University and his Ph.D. in 2016 from the University of Sussex. He continued at Sussex university working as a research and development chemist specialising in chemical process engineering and organic synthesis. He has a vast experience in catalytic processes and is credited with numerous publications on this subject. Additionally, Daniel has comprehensive practical knowledge of all aspects of analytical chemistry. Having collaborated with 113 Botanicals on a number of projects over the past four years through their partnership with the University of Sussex, he recently joined the 113 team as Principal Scientist. He is currently working on the development of novel processes related to cannabis based pharmaceutical products as well as undertaking a supervisory role in further academic partnerships between the university and 113 Botanicals. Background Daniel has worked on various medicinal chemistry projects through his work with the Sussex Drug Discovery Centre (SDDC) particularly focusing on the application of natural products for the development of novel therapeutics. He has worked with 113 Botanicals designing extraction apparatus and methodologies. He has collaborated with the University of Sussex pharmacy department, researching the application of cannabinoid extracts in the formulation of Cannabis-based products for medical use (CBPMs) and is currently working with Dr Barnaby W Greenland on the production of adhesive patches for transdermal drug delivery of cannabinoids. Additionally, and of great use to this project, Daniel has an expert level knowledge of 3D printers and, as such, at he can confidently make adaptations and modifications as required by the project’s needs.

Prof John
Spencer

Lead Scientific Advisor
John started out as an undergraduate at Sussex. After a 1st Class Hons ...

Read more

John Spencer
Lead Scientific Advisor

John started out as an undergraduate at Sussex. After a 1st Class Hons (Chemistry/French) he was awarded an Erasmus-funded PhD grant in palladium chemistry at the elite French Chemistry department in Strasbourg University, France, (ULP Louis Pasteur, in Michel Pfeffer’s group) then undertook postdoctoral studies on a Chiral2 scholarship at ETH, Zurich, with Prof Antonio Togni. He next spent a decade in small to medium biotech companies and start-ups, half of which were spent in the Nobel laureate, James Black Foundation, and had preclinical, Phase I and II clinical candidates in thrombosis (thrombin inhibitor) and cancer (CCK2 and PTH-1 antagonists).

With industrial leadership in medicinal chemistry and a consistent track record of successful project delivery and IP generation, John has secured several million pounds of external research funding from Research Councils, Charities (Niemann Pick Foundation, Blood Cancer UK, CRUK, Worldwide Cancer), EU and companies (e.g. AZ, GSK, Tocris). He has over 200 publications and patents, with >8500 citations and an H-index of 41, and has successfully trained over 25 PhD students and as many postdoctoral fellows.

He has a successful track record of mentoring junior colleagues in research strategy and grant bids and has held several positions of responsibility: Director of Drug Discovery Centre, previous Director of Research and Knowledge Exchange, committee member for new course generation (Pharmacy), PhD convenor for Department, UK grant committee chairman (RSC). He has an international external profile; 2 editorial board positions, regular invited editor for journals, invited academic positions abroad (Auckland), plenary and invited lectures. SAB member for Worldwide Cancer Research, Prostate Cancer UK, EPSRC Peer Review College member.

His role with 113-Botanicals is to help deliver the scientific vision, especially in terms of R&D and synthetic/medicinal chemistry.

Dr Barnaby
Greenland

Medicinal Chemistry
Dr Barny Greenland is a Senior Lecturer in Medicinal Chemistry at the University of Sussex. Having obtained his MSci (2002) and PhD (2007) from Imperial

Read more

Dr Barnaby Greenland
Lecturer In Medicinal Chemistry

Dr Barny Greenland is a Senior Lecturer in Medicinal Chemistry at the University of Sussex. Having obtained his MSci (2002) and PhD (2007) from Imperial College London, moved to take up a position as a Postdoctoral Research Fellow at the University of Reading. In 2017 he was appointed to his first permanent position as a Lecturer in Pharmaceutical Chemistry in the Reading School of Pharmacy.

In 2017 he moved to the University of Sussex where he was promoted to his current position in 2021. Barny has published over 65 research papers, reviews and book chapters in the fields of supramolecular and polymer chemistry including drug delivery. He has been working with 113 Botanicals since 2020, focussing on the extraction and delivery of cannabinoids for medical applications.

Hedaythul
Choudhury

Electrophysiologist
A highly motivated electrophysiologist with experience drug discovery research and assay development across different therapeutic areas ...

Read more

Shamin
Electrophysiologist

Hedaythul Chowdhery (Shamim) is a highly motivated electrophysiologist with experience in drug discovery research and assay development across different therapeutic areas including neuroscience & neurodegenerative diseases, respiratory (CF), Autoimmune & CNS diseases. Shamim has a broad range of transferable scientific skills that are vital in drug discovery research projects.

andrew-dilly-profile

Andrew
Dilly

Neuroscientist
Professor Andrew Dilley is a neuroscientist at the Brighton and Sussex Medical School. His research is focussed on understanding the role of peripheral ...

Read more
Andrew Dilly
Neuroscientist
Professor Andrew Dilley is a neuroscientist at the Brighton and Sussex Medical School. His research is focussed on understanding the role of peripheral neuroinflammation in chronic musculoskeletal pain, with the principal aim of establishing novel targets for treating chronic pain. Professor Dilley completed a BSc degree at University College London, a PhD at Kings College London, and postdoctoral training at University College London and Harvard Medical School.

Nour
Nashed

Research Consultant
Having published three academic papers in high ranked scientific journals, Nours impressive knowledge and research skills ...

Read more
Nour Nashed
Research Consultant
Holds a BSc(Hons.) degree in pharmacy from the University of Aleppo in Syria. Her high academic achievement enabled her to work as an assistant lecturer, as well as a community pharmacist, whilst attaining her master’s degree in pharmaceutical chemistry. This interdisciplinary education and practical experience ignited Nour’s specific interest in pharmaceutical science leading her to pursue a PhD in the UK. She was granted by the university of Sussex a full-time PhD in pharmaceutics specialising in the research into safe and effective medications and development of more efficacious routes of administration. Alongside her PhD programme, Nour continued to work as research assistant at the University of Sussex as well as under short term contract with several big pharma companies. As her PhD journey is coming to end, Nour could improve her interpersonal and research skills. Nour published three academic papers in high ranked scientific journals. Nours impressive knowledge and research skills in formulation development of oral dosage forms made her the obvious choice for inclusion in our technology team.

Charles
Monroe

Engineering Consultant
An engineering consultant with experience in the pharmaceutical and cryogenic sectors bringing innovative engineering to serve industry and research.

Read more

Charles Monroe
Engineering Consultant

Charles Monroe has worked as an engineer in the pharmaceutical and cryogenic sector bringing innovative engineering to serve industry and research.

He graduated from Cambridge University with a degree in Engineering in 1983 and subsequently qualified as a Chartered Engineer and a Fellow of the Institution of Mechanical Engineers. His first employment was with Oxford Instruments Ltd designing large superconducting magnets and the associated cooling systems. This was followed by work with the industrial gas company Air Products PLC and then Sapio Srl in Monza, Italy developing new liquid nitrogen cooling process for the pharmaceutical and chemical industries.

For the last twenty six years he has run his own business as an engineering consultant supplying innovation and expertise to industry and research laboratories in the UK, Europe, Canada and the USA. The processes have included cooling with liquid helium, liquid nitrogen, cryocoolers and conventional refrigeration. This has been applied to scientific instruments, superconducting magnets, radio telescopes, pharmaceutical and petrochemical processes, carbon capture and storage, hydrogen generation technologies, pollution abatement and fusion energy development.

Charles Monroe is the named inventor on several patents and has co-authored several papers and is regularly invited to give training talks at international conferences and meetings.

Andy
Marshall

Quality Consultant
Andy has been working with 113 Botanicals for the last two years and describes as a supportive, young and developing company with a bright future ...

Read more
Andy Marshall
Quality Consultant
Extensive experience in primary and secondary pharmaceutical Quality Management Systems, with knowledge of process, equipment and facility validation. Has performed lectures on a number of pharmaceutical-related subjects and has hosted and acted as a subject matter expert on quality and water systems (PW and WFI) during both MHRA and FDA regulatory inspections. Have performed audits throughout the world and has experience in working in different regions of the world within the pharmaceutical industry

Specialties

Quality Management, Change Control, Deviation and Non-Conformance systems, CAPA, cGMP, FDA, MHRA, Validation (process, facilities and equipment), Training, Auditing, Purified Water and Water For Injection Systems. API and secondary manufacturing processes.

Our Management Team

Les
Maguire

CEO and Co-Founder
Leslie has been with 113 since it's inception and has driven the formation and development of the company infrastructure and production site ...

Read more
Les Maguire CEO
Expertise in building businesses from start-up to nationwide in scale. Since 113's inception, Leslie has led the strategic direction of the business and driven the formation and development of the company’s infrastructure and production site development.

Kate
Cook

COO and Co-Founder
20 years experience in international recruitment and HR for corporate finance, pharmaceutical and biotech. Currently a member of Cannabis industry ...

Read more

Kate Cook
COO

Kate has over 20 years working
within Recruitment and HR, in the UK and internationally. Kate has had exposure to a huge array of industries from corporate finance and regulatory bodies through to pharmaceutical and biotech. Kate is an active member of the Environmental & Social Governance
Subcommittee for the Cannabis
Industry Council (CIC).

Simon
Price

CFO
25 years experience in investment markets and asset management. Lead analyst in several IPO's and equity capital rises in both the UK and ...

Read more

Simon Price
CFO

Simon has over 25 years’ experience in equity markets, in a career spanning both Investment Banking and Asset Management. In his 10 years Investment Banking experience, including roles at Merrill Lynch, Schroders and JP Morgan, he was lead analyst on several IPOs and equity capital raises in both UK and European markets.. Since 2018, Simon has been an active Angel investor, including a founding investment in a Fintech company and early stage
investments in a variety of ventures.

Tim
Kneen

CSO
A strategic thinker in the Pharmaceutical industry with over 20 years experience leading large and complex businesses. Specialising in mature, emerging markets.

Read more
Tim Keen CSO
Tim is a strategic thinker specializing in challenging, complex mature and emerging markets. Specialist in the Pharmaceutical Industry, with over 20 years at Merck: Global, Regional President & General Management - P&L Management and leadership of large and complex business.

Kieron
Williams

Head of Procurement
Part of 113 since its inception. Kieron has worked on building a robust supply chain, sourcing suppliers and crafting our distribution channels...

Read more
Kieron Williams Head Of Procurement
With the team since its inception, Kieron has worked on the initial set-up through to building a robust supply chain going forward. Sourcing suppliers, researching costs and looking ahead to distribution channels. Also acts as our representative on two CIC subcommittees and liaises with patient groups.